What were Shilpa Medicare Ltd's latest quarterly results?
Shilpa Medicare Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: +40.6%
- Revenue Growth YoY: +28.5%
- Operating Margin: 28.0%
Shilpa Medicare Ltd (Pharma - API & CRAMS) — fundamental analysis, earnings data, and key metrics. PE: 38.6. ROE: 4.2%. This stock is not currently in the Nifty 500 momentum outperformers list.
Based on publicly available financial data. This is educational research, not investment advice.
Shilpa Medicare Ltd's latest quarterly results (Dec 2025) show
Shilpa Medicare Ltd's current PE ratio is 38.6x.
Shilpa Medicare Ltd's price-to-book ratio is 2.8x.
Shilpa Medicare Ltd's fundamental strength based on key financial ratios
Shilpa Medicare Ltd has a debt-to-equity ratio of N/A.
Shilpa Medicare Ltd's return ratios over recent years
Shilpa Medicare Ltd's operating cash flow is positive (FY2025).
Shilpa Medicare Ltd's current dividend yield is 0.14%.
Shilpa Medicare Ltd's shareholding pattern (Dec 2025)
Shilpa Medicare Ltd's promoter holding has decreased recently.
Shilpa Medicare Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Based on quantitative research signals, here is why Shilpa Medicare Ltd may be worth studying
Shilpa Medicare Ltd investment thesis summary:
Shilpa Medicare Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.